BiotechTube
HD Immune

HD Immune

Vienna, Austria· Est.
hdimmune.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

HD Immune is a private, preclinical-stage biotech developing a monoclonal antibody therapy for Huntington's disease. Its approach targets extracellular mutant huntingtin protein to block its intercellular transmission and spread of pathology, aiming to slow disease progression. The company leverages proprietary knowledge and published research from its founder, Dr. Stefan Bartl, and maintains international research collaborations. As a pre-revenue entity, its primary focus is on optimizing its lead candidate for future human clinical trials.

NeurologyNeurodegenerative Diseases

Technology Platform

Monoclonal antibody platform targeting extracellular mutant huntingtin protein to block intercellular transmission and pathology spread in Huntington's disease.

Opportunities

The approval of Lecanemab for Alzheimer's validates the antibody approach in neurodegeneration, potentially de-risking the regulatory path.
The high unmet need in Huntington's disease, an orphan indication, allows for premium pricing and accelerated regulatory pathways.
The clear genetic diagnosis enables potential treatment in pre-symptomatic individuals, expanding the addressable patient population.

Risk Factors

The lead program is in preclinical development, with a high risk of failure in translating animal data to human efficacy and safety.
The company is a single-asset, pre-revenue entity with undisclosed funding, facing significant financial and dilution risk.
It competes with more advanced programs (e.g., gene-silencing therapies) from larger companies, creating a challenging competitive landscape.

Competitive Landscape

The HD therapeutic landscape is competitive, with several companies advancing RNA-targeting therapies (e.g., ASOs, siRNA from Roche/Ionis, Wave Life Sciences, UniQure) that are in later-stage clinical trials. HD Immune's antibody approach is mechanistically distinct, targeting extracellular protein versus intracellular RNA, potentially offering a different safety and delivery profile. Other antibody approaches for HD exist but are less prominent, leaving room for a first-in-class entrant if clinical data are strong.

More companies in Biologics / Biosimilars →More companies in Austria →